Building on these evidences, targeting PD-L1/PD1 axis has become an attractive immunotherapeutic strategy and, indeed, its clinical value has been confirmed in a number of human cancers, such as melanoma, lung cancer, and renal cell carcinoma, but not in PCa, mPCa included, except in a small cohort of selected patients and in combination with other standard therapies [16,17,18,19]. This evidence concerns the gene PDCD1 and posterior cortical atrophy.